{
  "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
  "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 60,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the competitive advantage of NXC-201.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/11",
  "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
  "deckJsonHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9.json",
  "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "callout",
      "text": "Optimized (Decreased) CD8 Hinge Flexibility Results in Zero Neurotoxicity, Improved Human Efficacy, and reduction in CRS duration",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e9fec9d-cb43-4649-9d42-afed78fe71c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Preclinical cytokine release comparison",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a3c6dd6-4a0a-48ba-8a1d-f022467692a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source:: Ying Z, et al. Nat Med. 2019; Schuster SJ, et al. N Engl J Med. 2019; Assayag, M., et al EBMT 2023; Abecma FDA label; Harush O, et al. Haematologica. 2022; Friedman KM, et al. Hum Gene Ther. 2018. Kymriah: Preclinical is an average of CD8+ and CD4+ T-cells, source: Milone MC, et al. AL. Mol Ther. 2009 Aug;17(8):1453-64. doi: 10.1038/mt.2009.83. Epub 2009 Apr 21. Erratum in: Mol Ther. 2015 Jul;23(7):1278. PMID: 19384291; PMCID: PMC2805264.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6e3ef23-61d4-4fb3-881e-c8565fc7fbe3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "table",
      "text": "Clinical efficacy and safety comparison table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48957ff2-f519-41c3-b233-2d67bad1ccc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.08,
        "y": 0.03
      },
      "kind": "title",
      "text": "Proprietary Optimized CD3ζ + CD8 Delivers “Digital” Intracellular Signaling, Eliminates Neurotoxicity, Reduces CRS Duration",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30de5916-041d-4df9-9068-71177a952ff5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "174efa91-6589-4d64-baf0-bb5d5bbccbbb",
      "evidence": "Direct comparison of clinical and preclinical metrics between NXC-201 and industry standards.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 22,
      "from": 11,
      "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Competitive Analysis",
      "beatSlug": "sequoia-pitch-competition",
      "evidence": "Slides 11-22: Various competitive analysis slides",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7d11637b-9390-42ac-9fbe-a23167bc5c6a",
      "evidence": "Slides 7-14 discuss the limitations of current CAR-T therapies due to neurotoxicity",
      "position": 0,
      "objective": "What are the consequences of not addressing neurotoxicity in CAR-T therapy?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 60,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
      "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
      "position": 1,
      "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}